Market Place
Sourcing Support
FDA approves Celltrion`s Steqeyma, a biosimilar to Stelara
18 Dec 2024 //
PRNEWSWIRE
Celltrion`s Biologic Stqeyma Receives Suppl Approval in US
17 Dec 2024 //
FDA
Celltrion Presents Phase III Data for CT-41 & CT-P47 Biosimilars
18 Nov 2024 //
PR NEWSWIRE
Celltrion`s Biologic Herzuma Receives Suppl Approval in US
14 Nov 2024 //
FDA
Celltrion Acquires iQone Healthcare to Expand European Expertise
14 Nov 2024 //
BUSINESSWIRE
Zymfentra® Coverage Increases with Top 3 PBM Partnership
31 Oct 2024 //
PR NEWSWIRE
Celltrion Presents Analysis Of Liberty Studies For Zymfentra®
29 Oct 2024 //
PR NEWSWIRE
Celltrion Presents 2-Year Findings For Infliximab (CT-P13 SC) In IBD
15 Oct 2024 //
BUSINESSWIRE
Celltrion`s Steqeyma (ustekinumab) Receives Approval in Europe
11 Sep 2024 //
EMA
EC Approves Celltrion`s SteQeyma For Multiple Inflammatory Diseases
26 Aug 2024 //
BUSINESSWIRE
Celltrion`s Humira Biosimilar Added To Costco Prescription Program
12 Aug 2024 //
PR NEWSWIRE
Health Canada Approves Celltrion`s Steqeyma® For Inflammatory Conditions
01 Aug 2024 //
BUSINESSWIRE
Chinese startup Hasten Biopharma buys 14 products from Korean firm Celltrion
02 Jul 2024 //
BIOSPECTRUM ASIA
Celltrion showcases promising results in phase III study for CT-P47
13 Jun 2024 //
BUSINESSWIRE
Celltrion Healthcare`s Omlyclo (omalizumab) Receives Approval in the Europe
29 May 2024 //
EMA
EC approves Celltrion’s Omlyclo for allergic conditions
24 May 2024 //
PHARMACEUTICAL TECHNOLOGY
Celltrion Omlyclo® Ec Approval: First Omalizumab Biosimilar In Europe
23 May 2024 //
BUSINESSWIRE
ZYMFENTRA Demonstrates 2-Year Crohn`s, UC Efficacy, Safety Profile
21 May 2024 //
PR NEWSWIRE
Reality TV star, Mollie Pearce, backs campaign to tackle in condition
20 May 2024 //
PHARMIWEB
Reality Star Backs Campaign On Condition Impacting Millions
18 May 2024 //
BUSINESSWIRE
Celltrion HUMIRA Biosimilar At Low Wholesale Acquisition Cost
09 May 2024 //
PR NEWSWIRE
Celltrion USA, Express Scripts Deal For ZYMFENTRA™ & Autoimmune Therapies
28 Apr 2024 //
PR NEWSWIRE
Celltrion USA completes submission of BLA to U.S. FDA for CT-P39
10 Mar 2024 //
PR NEWSWIRE
Celltrion presents new two-year data for subcutaneous infliximab (CT-P13 SC)
23 Feb 2024 //
BUSINESSWIRE
Health Canada Approves Remsima™ SC for the Treatment of IBD
18 Feb 2024 //
BUSINESSWIRE
Celltrion USA completes submission of Biologics License Application for CT-P47
28 Jan 2024 //
PR NEWSWIRE
Newly spun-off WuXi XDC locks up ADC deal with Korea`s Celltrion
24 Jan 2024 //
FIERCE PHARMA
Celltrion`s Biologic Yuflyma (adalimumab) Receives Approval in the U.S.
30 Nov 2023 //
FDA
Celltrion USA announces distribution and incorporation of YUFLYMA
26 Oct 2023 //
BUSINESSWIRE
Celltrion & Celltrion Healthcare Announce Shareholders Approval of Merger
23 Oct 2023 //
BUSINESSWIRE
Celltrion USA Announces U.S. FDA Approval of ZYMFENTRA
23 Oct 2023 //
BUSINESSWIRE
Celltrion`s Biologic Zymfentra (infliximab) Receives Approval in the U.S.
20 Oct 2023 //
FDA
Data Presented Support the Potential of Celltrion’s Infliximab CT-P13
16 Oct 2023 //
BUSINESSWIRE
Celltrion USA has signed a contract with Ventegra® to add Yuflyma
05 Oct 2023 //
BUSINESSWIRE
Celltrion Celebrates a Decade of Biosimilar Innovation in Europe
10 Sep 2023 //
BUSINESSWIRE
Celltrion`s Biologic Yuflyma (Adalimumab) Receives Approval in the U.S.
06 Sep 2023 //
FDA
Celltrion to Participate in the Morgan Stanley 21st Annual Global Conference
06 Sep 2023 //
BUSINESSWIRE
Celltrion`s Regkirona regdanvimab Receives Approval in Europe
25 Aug 2023 //
EMA
Celltrion`s Yuflyma (adalimumab) Receives Approval in Europe
18 Jul 2023 //
EMA
Celltrion launches biosimilar of AbbVie`s blockbuster drug Humira in US
06 Jul 2023 //
REUTERS
Celltrion Launches Yuflyma on the US Market
03 Jul 2023 //
CENTER FOR BIOSIMILARS
Rani Therapeutics expands biologics partnership with Korean firm Celltrion
07 Jun 2023 //
BIOSPECTRUM ASIA
Celltrion USA Announces U.S. FDA Approval of Yuflyma® (adalimumab-aaty)
24 May 2023 //
BUSINESSWIRE
Celltrion`s Biologic Yuflyma (Adalimumab) Receives Approval in the U.S.
23 May 2023 //
FDA
Celltrion campaign wants you to find `hidden characters` of IBD
19 May 2023 //
FIERCE PHARMA
Bora Pharma, Celltrion Partner to Expand OSD Capabilities in the APAC Market
06 Apr 2023 //
CONTRACT PHARMA
Celltrion Healthcare`s Vegzelma (bevacizumab) Receives Approval in Europe
22 Mar 2023 //
EMA
Baxter`s for-sale CMO attracts Thermo Fisher, Celltrion
22 Mar 2023 //
FIERCE PHARMA
Celltrion Healthcare Presents Efficacy and Safety Data From PIII LIBERTY Trial
03 Mar 2023 //
BUSINESSWIRE
Celltrion & LISCure announce collaboration for Parkinson`s disease
20 Feb 2023 //
PR NEWSWIRE
Celltrion signs up to support oral biosimilar of J&J’s Stelara
10 Jan 2023 //
FIERCEPHARMA
Celltrion and Rani Therapeutics Partner on Development of Antibody Treatment
09 Jan 2023 //
GLOBENEWSWIRE
Celltrion submits application for CT-P13 SC to FDA
22 Dec 2022 //
PHARMAFILE
Celltrion USA announces submission of the (BLA) novel sub formulation of CT-P13
22 Dec 2022 //
BUSINESSWIRE
Brand Institute Partners on Brand Name Dev for Approved Biologic Medication
19 Oct 2022 //
PRNEWSWIRE
Celltrion USA Receives U.S. FDA Approval for its Oncology Biosimilar Vegzelma
28 Sep 2022 //
BUSINESSWIRE
Celltrion`s Biologic Vegzelma (Bevacizumab) Receives Approval in the U.S.
27 Sep 2022 //
FDA
Celltrion’s anticancer biosimilar Vegzelma authorized for sales in Japan
27 Sep 2022 //
KOREABIOMED
Abpro to Partnership with Celltrion for Development of a Antibody
22 Sep 2022 //
BUSINESSWIRE
Celltrion’s Vegzelma receives EC approval for cancer treatments
19 Aug 2022 //
PHARMACEUTICAL TECHNOLOGY
